Concepedia

David I. Bellovin

DI

20

Publications

2.2K

Citations

18

H-Index

2005

Active since

Affiliations

Stanford University(Current)

Five Prime Therapeutics (United States)

Harvard University

Johns Hopkins University

Yale University

David I. Bellovin is an author at Stanford University specializing in cancer research, medicine, and tumor biology.

ORCID

Top concepts

Publications per year

2005–2022

20

Publications

20

Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

Richard C. Bates, David I. Bellovin, Courtney Brown et al. · Journal of Clinical Investigation · 2005 · 327 citations · Full text

Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

Richard C. Bates, David I. Bellovin, Courtney Brown et al. · Journal of Clinical Investigation · 2005 · 301 citations · Full text

, , +16

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells

Brian J. Altman, Annie L. Hsieh, Arjun Sengupta et al. · Cell Metabolism · 2015 · 270 citations · Full text

, , +11

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

Emelyn H. Shroff, Lívia S. Eberlin, Vanessa Dang et al. · Proceedings of the National Academy of Sciences · 2015 · 252 citations · Full text

, , +13

MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase

Zhongwei Cao, Hua Fan-Minogue, David I. Bellovin et al. · Cancer Research · 2011 · 175 citations · Full text

, , +17

Rows per page

1–5 of 20